Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Viridian Therapeutics, Inc. (VRDN) reported a Q4 loss of $0.81 per share, which was better than the Zacks Consensus Estimate of a $1.05 loss. This is an improvement from the $1.35 loss per share reported a year ago.
February 27, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics reported a Q4 loss of $0.81 per share, better than the expected $1.05 loss, showing improvement from last year's $1.35 loss.
The better-than-expected earnings report suggests positive sentiment for VRDN, as the company reduced its losses compared to both the estimate and the previous year. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100